Monitoring Timeline for adult patients receiving GATTEX
Within 6 months prior to starting GATTEX treatment1:
- Perform a colonoscopy of the entire colon with removal of polyps1
- Obtain baseline laboratory assessments (bilirubin, alkaline phosphatase, lipase, and amylase)1
Ongoing | Every 6 months |
After 1 year of GATTEX* |
At least every 5 years |
||
---|---|---|---|---|---|
Colonoscopy1 | Examination of the entire colon with removal of polyps |
|
|
||
Laboratory assessments1 |
Bilirubin |
|
|||
Alkaline phosphatase |
|
||||
Lipase |
|
||||
Amylase |
|
||||
Clinical evaluations1 | Signs and symptoms of intestinal obstruction |
|
|||
Signs and symptoms of fluid imbalance and fluid overload |
|
||||
Increased absorption of concomitant oral medication(s) |
|
||||
Observation of other adverse events |
|
Colonoscopy after 1 year of GATTEX* and at least every 5 years1 |
---|
Examination of the entire colon with removal of polyps |
Laboratory assessments every 6 months1 |
Bilirubin |
Alkaline phosphatase |
Lipase |
Amylase |
Ongoing clinical evaluations1 |
Signs and symptoms of intestinal obstruction |
Signs and symptoms of fluid imbalance and fluid overload |
Increased absorption of concomitant oral medication(s) |
Observation of other adverse events |
Discontinuation of treatment with GATTEX may result in fluid and electrolyte imbalance. Fluid and electrolyte status should be monitored in patients who discontinue treatment with GATTEX.1
*Follow-up colonoscopy (or alternate imaging) is recommended at the end of 1 year of treatment with GATTEX.1
See how to get your appropriate patients started, or keep reading for information on dosing.
Monitoring timeline for pediatric patients receiving GATTEX
Within 6 months prior to starting GATTEX treatment1:
- Perform fecal occult blood testing; if there is unexplained blood in the stool, perform colonoscopy/sigmoidoscopy1
- Obtain baseline laboratory assessments (bilirubin, alkaline phosphatase, lipase, and amylase)1
Ongoing | Every 6 months |
After 1 year of GATTEX¶¶¶ |
Every year |
At least every 5 years |
||
---|---|---|---|---|---|---|
Fecal occult blood test1 |
Examine for unexplained blood in stool |
|
||||
Colonoscopy/ Sigmoidoscopy1¶¶¶ |
Assess for colorectal polyps |
|
|
|||
Laboratory assessments1 | Bilirubin |
|
||||
Alkaline phosphatase |
|
|||||
Lipase |
|
|||||
Amylase |
|
|||||
Clinical evaluations1 |
Signs and symptoms of intestinal obstruction |
|
||||
Signs and symptoms of fluid imbalance and fluid overload |
|
|||||
Increased absorption of concomitant oral medication(s) |
|
|||||
Observation of other adverse events |
|
Fecal occult blood test every year1 |
---|
Examine for unexplained blood in stool |
Colonoscopy/Sigmoidoscopy after 1 year of GATTEX and every 5 years thereafter 1¶¶¶ |
Assess for colorectal polyps |
Laboratory assessments every 6 months1 |
Bilirubin |
Alkaline phosphatase |
Lipase |
Amylase |
Ongoing Clinical Evaluations1 |
Signs and symptoms of intestinal obstruction |
Signs and symptoms of fluid imbalance and fluid overload |
Increased absorption of concomitant oral medication(s) |
Observation of other adverse events |
Discontinuation of treatment with GATTEX may result in fluid and electrolyte imbalance. Fluid and electrolyte status should be monitored in patients who discontinue treatment with GATTEX.1
¶¶¶Colonoscopy/sigmoidoscopy is recommended for all children and adolescents after 1 year of treatment, every 5 years thereafter while on continuous treatment with GATTEX, and if they have new or unexplained gastrointestinal bleeding.1
See how to get your appropriate patients started, or keep reading for information on dosing.